Emverm Approved to Treat Systemic Worms
January 15, 2016 – Impax Laboratories announced that the U.S. Food and Drug Administration (FDA) approved Emverm (mebendazole). Emverm is indicated for the treatment of several kinds of hookworms, pinworms, roundworms, and whipworms. Mebendazole was first approved in 1974 as an anti-worm drug. Emverm is recommended to be taken as one 100mg chewable tablet, twice a day for three days, and repeated after three weeks if the infestation does not clear. Estimated launch date for Emverm is scheduled for the second quarter of 2016.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.